On January 16, 2020, the Anesthetic and Analgesic Drug Products Advisory Committee is scheduled to review DURECT Corp.’s (DRRX) resubmitted New Drug Application for POSIMIR, a post-operative pain relief depot.POSIMIR, a nonopioid, locally-acting analgesic, is designed to be administered directly into the surgical site to deliver the anesthetic bupivacaine for up to three days after surgery.The FDA had issued a Complete Response Letter for POSIMIR in February 2014.DRRX closed Monday’s (Dec.30, 2019) trading at $3.53, up 8.28%.